Taiho Oncology, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2002-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.taihooncology.com
Evaluating Patients With Impaired Hepatic Function
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00398424
- Locations
- 🇺🇸
University of Kentucky/Division of Hematology/Oncology and Blood Marrow Transplantation, Lexington, Kentucky, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸The Institute for Drug Development, San Antonio, Texas, United States
Evaluating Patients With Varying Degrees of Renal Function
Phase 1
Completed
- Conditions
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00398307
- Locations
- 🇺🇸
LAC/USC Medical Center, Los Angeles, California, United States
🇺🇸Premiere Oncology of Arizona, Scottsdale, Arizona, United States
🇺🇸Premiere Oncology, Santa Monica, California, United States
Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer
Phase 1
Completed
- Conditions
- First Posted Date
- 2003-11-13
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT00072787
- Locations
- 🇺🇸
Lovelace Sandia Health System, Albuquerque, New Mexico, United States
🇺🇸University of New Mexico - Albuquerque, Albuquerque, New Mexico, United States
🇺🇸New Mexico VA Health Care System, Albuquerque, New Mexico, United States
© Copyright 2024. All Rights Reserved by MedPath